Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in <i>BRCA</i> Carrier Ovarian Cancer Correlating With Platinum-Free Interval

C.C. Fong, Peter; A. Yap, Timothy; S. Boss, David; P. Carden, Craig; Mergui‐Roelvink, Marja; Gourley, Charlie; De Grève, Jacques; Lubiński, Jan; Shanley, Susan; Messiou, Christina; A’Hern, Roger; Tutt, Andrew; Ashworth, Alan; Stone, John; Carmichael, James; H.M. Schellens, Jan; S. de Bono, Johann; B. Kaye, Stan

doi:10.1200/jco.2009.26.9589

Public

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

Published in Journal of Clinical Oncology • Apr 20, 2010

Authors:

Peter C.C. Fong

Timothy A. Yap

David S. Boss

Abstract

PURPOSE: Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA repair. Platinum-based chemotherapy responses co...

Subject

Olaparib

Medicine

Ovarian cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!